Cardiac involvement in light-chain amyloidosis (AL) predicts poor prognosis and is associated with higher TRM and morbidity during high-dose therapy and auto-SCT (HDT-ASCT). We studied the outcomes of 30 patients with cardiac amyloidosis undergoing HDT-ASCT at our center between January 1998 and March 2012. The median age of the patients was 53 years (range, 36-74) with a median follow-up of 35 months (range, 0.4-97 months). Twenty-seven patients (90%) had more than one organ involved besides the heart with 37% with cardiac stage ⩾ 3. Melphalan-based conditioning regimen (140-200 mg/m 2 ) was used for HDT-ASCT. One-year TRM is 10%. Three-year OS and EFS from HDT-ASCT was 83% and 56.8%, respectively. Cumulative incidence of relapse at 3 years was 38.5%. Negative factors affecting survival included age 460 years, lack of novel induction therapy and BM plasmacytosis 410%. We conclude that HDT-ASCT is well tolerated in patients with high-risk cardiac amyloidosis and can lead to improved overall outcomes.
INTRODUCTION

Cardiac involvement in patients with light-chain amyloidosis (AL)
is a life threatening illness that can lead to serious morbidity and increased mortality. 1 Especially, patients with overt signs of congestive heart failure have a median survival of only 4 months. 2 Incorporation of cardiac biomarkers including brain natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP) as well as cardiac troponins for prognostication and risk assessment has led to early detection of patients at risk so that early intervention can be instituted. 3 Dispenzieri et al. 4 reported the outcomes of 261 newly diagnosed primary systemic amyloidosis patients, where the median survival for patients with detectable cardiac troponin-T (cTnT) and cardiac troponin-I (cTnI) was 6 and 8 months, respectively, are significantly worse than that for those with undetectable values (22 and 21 months, respectively). 5 Other studies have also reported the prognostic significance of markers of cardiac injury and dysfunction in the patients with AL. 6 Given the significant impact of cardiac involvement on the outcomes, cardiac markers (cTnT, cTnI, BNP and NT-proBNP) have now been incorporated in the routine staging. 5 According to the revised prognostic scoring system from the Mayo Clinic, patients are assigned a score of 1 for each of the difference between involved and uninvolved free light chain ⩾ 18 mg/dL, cTnT ⩾ 0.025 ng/mL and NT-proBNP ⩾ 1800 pg/mL. The median overall survival of the patients with Mayo stage I, II, III, and IV (score 0, 1, 2, and 3 respectively) is 94.1, 40.3, 14, and 5.8 months, respectively. 7 Successful treatment of AL remains a challenge owing to severe organ dysfunction, particularly in those patients with cardiac involvement. The outcome is dismal with conventional chemotherapy, with survival ranging from 5 to 17 months depending on the proportion of the patients with cardiac involvement. 8 Cardiac responses are observed only in 0-26%, whereas the early mortality rate is 23-40%. [8] [9] [10] High-dose therapy with auto-SCT (HDT-ASCT) has been shown to be associated with long-term survival in AL patients. [11] [12] [13] [14] [15] However, high TRM ranging from 13 to 43%, especially in patients with cardiac involvement, questions the applicability of this treatment modality. 16 In order to answer this question, we performed a retrospective analysis of AL patients with cardiac involvement undergoing HDT-ASCT at our center.
PATIENTS AND METHODS
In the period of January 1998-March 2012, a total of 264 patients with diagnosis of systemic AL at the University of Texas MD Anderson Cancer Center were reviewed under an Institutional Review Board-approved protocol, where 53 patients had documented cardiac involvement as defined by either an endomyocardial biopsy or echocardiographic evidence of an infiltrative cardiomyopathy. Among this group, 30 patients with cardiac amyloidosis underwent HDT-ASCT. Cardiac staging was assessed using the Mayo prognostic staging system. 5 HDT-ASCT was performed using high-dose melphalan 140-200 mg/m 2 conditioning regimen followed by autologous peripheral blood stem cell infusion. The choice and dose of the conditioning regimen were based on the treating physician's decision and the patient's performance status. All patients routinely received growth factor support after HDT-ASCT. They were mobilized in the inpatient setting. All patients underwent cardiology consultation at the time of admission for transplant. Decisions regarding transfer to the intensive care unit (ICU) were based on the patient's condition, development of new arrhythmia requiring monitoring and intervention, hypotension, desaturation and based on the attending physician's discretion.
Hematologic and organ response
Hematologic response (HR) and cardiac response were evaluated at 1-year post-HDT-ASCT using the criteria established by the tenth International Symposium on Amyloid and Amyloidosis. 17 Complete HR (CHR) requires the absence of serum and urine M-protein by immunofixation, and a normal free light-chain ratio along with BM plasmacytosis o5%. Partial HR (PHR) requires 450% reduction in serum M-protein, 24-h urine monoclonal lightchain excretion and the involved serum free light-chain concentration. Cardiac response was defined by more than 20% relative improvement in ejection fraction (EF), ⩾ 2 mm reduction in the interventricular septal thickness or improvement by 2 New York Heart Association classes without an increase in diuretic use and no increase in wall thickness.
Statistical analysis
The primary outcomes were OS and TRM. Secondary endpoints were hematologic and cardiac response, EFS and cumulative incidence of relapse. OS was defined as the time between HDT-ASCT and death from any cause; surviving patients were censored at the date of last contact. TRM was defined as death related to HDT-ASCT in the absence of relapse. EFS was defined as the time between HDT-ASCT and disease relapse or death from any cause; data for the patients who were alive without relapse were censored at the date of last contact. Relapse was defined as hematologic or cardiac progression according to standard criteria. OS and EFS were calculated using the Kaplan-Meier method, 18 and the log-rank test was used to compare individual factors. The significant factors in the univariate analysis were subsequently chosen to evaluate the effect on the survival outcomes in Cox regression analysis. 19 All factors were tested for the proportional hazards assumption. Analyses were performed using SPSS 20.0 statistic software (IBM, Chicago, IL, USA). A P-value o 0.05 was considered to be statistically significant.
RESULTS
Patient characteristics
The median age at the time of transplant was 53 years (range, 36-74 years). Of the 30 cardiac amyloidosis patients, 22 (73%) were male, 24 (80%) patients had lambda AL and 27 (90%) had more than one organ involved besides the heart. This included the kidney in 18 (60%), the gastrointestinal tract in 7 (23%), the nervous system in the form of neuropathy in 7 (23%), the liver in 2 (7%) and the lung in 1 (3%). Stage III or higher cardiac staging was observed in 11 patients (37%). The median EF at the time of transplant was 53%, while the median interventricular septal thickness was 15 mm (0.97-2.1 mm). The median levels of cardiac biomarkers were the following: cTnT = 0.05 ng/mL (0.02-0.22 ng/mL), cTnI = 0.06 ng/mL (0-9.09 ng/mL), BNP = 315 pg/mL (15-47 000 pg/mL) and NT-proBNP = 2045.5 pg/mL (19-60 000 pg/ mL). Twenty patients (66%) experienced cardiac events before HDT-ASCT, including arrhythmia (16.6%), congestive heart failure (43%), syncope (13%) and pericardial effusion (3.3%). Three patients (10%) were admitted to the ICU owing to cardiac complications from AL before HDT-ASCT. The baseline clinical and laboratory features are listed in Table 1 .
Twenty-six patients (87%) received at least one cycle of induction chemotherapy and 24 (80%) of those received novel agent (lenalidomide, bortezomib and thalidomide)-containing regimens. Eighteen patients (60%) achieved HR with induction chemotherapy, including 1 and 17 patients with CHR and PHR, respectively. A decrease in interventricular septal thickness was seen in 4 patients (13%), but none of them had improvement of their EF before HDT-ASCT.
Transplant characteristics
The median duration from diagnosis to transplant was 6 months (range, 3-95 months). At the time of last follow-up, 17 patients were alive with a median estimated follow-up from HDT-ASCT of 34.5 months (range, 0.36-96.8 months). A total of 28 patients underwent peripheral blood stem cell mobilization using G-CSF alone, 1 patient received G-CSF plus plerixafor and 1 patient received G-CSF plus CY mobilization. Five patients underwent HDT-ASCT using a reduced-dose melphalan conditioning regimen, including 4 (13%) and 1 (3%) patients who received melphalan at 140 or 180 mg/m 2 , respectively, whereas the remaining patients received standard melphalan dose at 200 mg/m 2 . Twenty-seven patients (90%) underwent HDT-ASCT as an inpatient setting with median admission duration of 20 days (range, 6-48 days).
Transplant complications and responses Cardiac complications during stem cell mobilization and collection were observed in 3 patients (10%), including 2 patients with congestive heart failure and 1 who developed cardiac arrhythmia (atrial fibrillation). A total of 29 patients (96.7%) was engrafted with a median time to neutrophil and platelet engraftment of 10 and 11 days, respectively. Ten patients (33%) suffered cardiac Abbreviations: BNP = brain natriuretic peptide; EF = ejection fraction; FLC-diff = the difference between involved and uninvolved free light chain; GI = gastrointestinal; HDT-ASCT = high-dose therapy with auto-SCT; ICU = intensive care unit; IVS = interventricular septal thickness; LDH = lactate dehydrogenase; NT-proBNP = N-terminal pro-brain natriuretic peptide.
High-dose therapy in high-risk cardiac AL P Kongtim et al complications during HDT-ASCT, including congestive heart failure (23.3%), cardiac arrhythmia (16.6%) and syncope (3.3%).
No complications were reported among the 3 patients who underwent HDT-ASCT as outpatients. Of 27 patients who underwent inpatient HDT-ASCT, 10 patients (33%) required intensive care and 8 patients (30%) were readmitted within 100 days after HDT-ASCT. The causes of readmission were infection (11%), congestive heart failure (7.6%), diarrhea and gastrointestinal bleeding (11%). One patient who had cardiac and kidney involvement died without engraftment at day 11 post transplant due to cardiac arrhythmia and congestive heart failure. Overall, 1-year TRM was 10% and only one out of the stage III or higher cardiac amyloidosis patients died at 1-year post transplant. The overall HR was evaluated in 22 patients, with a response rate of 86.4%, including CHR in 22.7% and PHR in 63.7%. Cardiac response at 1-year post transplant was observed in 3 out of 13 evaluable patients (23%).
OS
The 3-year and 5-year OS for the whole cohort was 75% and 46%, respectively. We examined the following factors: age at HDT-ASCT, type of Ig light chain, the difference between involved and uninvolved free light chain, Hb level, percentage of plasma cells in the BM, serum albumin, creatinine, lactate dehydrogenase, B2 microglobulin, number of organs involved, EF, interventricular septal thickness, cTnT, cTnI, BNP, NT-proBNP, cardiac event and ICU admission before HDT-ASCT, induction therapy, novel agent therapy before HDT-ASCT, hematologic response before HDT-ASCT and reduced-dose melphalan conditioning. Significant factors impacting OS included the patients older than 60 years, with a 3-year OS from HDT-ASCT of 52% vs 87% in younger patients (P = 0.02; Figure 1a) ; novel agents as a part of induction therapy before HDT-ASCT, with a 3-year OS of 72% vs 62% (P = 0.08; Figure 1b) ; BM plasma cells at time of diagnosis o 10%, with a 3-year OS of 93% vs 59% in those with a higher plasma cell number (P = 0.002; Figure 1c) ; hematologic relapse post transplant with 3-year OS of 64% vs 88% (P = 0.03; Figure 1d ). EF o 60% at 1-year post transplant showed a trend toward poor outcome (P = 0.07). Only novel agent therapy before transplant showed trend toward significance in Cox regression analysis (HR 4.9; 95% confidence interval 0.78-29.4; P = 0.09). EFS Three-year EFS was 49%. In multivariate analysis, only BM plasma cells at time of diagnosis o10% were significant (HR 0.2; 95% confidence interval 0.05-0.8; P = 0.02; 3-year EFS: 87% vs 17%; P = 0.003; Figure 2 ).
Relapse
The cumulative incidence of relapse at 3 years was 38.5% (95%CI, 23-62). Cardiac progression at last follow-up was seen in 1 patient. There was no baseline and transplant characteristic associated with relapse rate.
DISCUSSION
In the current study, we report 1-year TRM of 10% that is far less than the published data of up to 43% TRM. 16, 20, 21 At our center, majority of the AL patients undergo mobilization and transplantation as inpatients with close cardiac monitoring. Lower mortality is also supported by improved supportive care and greater experience, and high-risk transplant for cardiac amyloidosis being performed at selected centers with higher expertise. 12 Although the median duration of hospitalization of 20 days was comparable to that for patients with multiple myeloma undergoing transplant, a higher rate of ICU transfer was noted primarily due to cardiac complications at our center. As we utilize a low threshold for ICU transfers for transplant patients with cardiac arrhythmias, it may have contributed to the improved overall mortality and outcome.
In the current study, HR was observed in 86% of the patients at 1-year post transplant with 23% CHR, comparable to the previous reports including Madan et al., 14 where a HR of 66% and CHR of 30% were reported in 187 cardiac amyloidosis patients, and Girnius et al., 22 where 27% CHR in 47 cardiac amyloidosis patients was reported in HDT-ASCT setting. However, as opposed to the recent data reported by the Mayo group, 23 HR before transplant (63%) or in the immediate post-transplant setting (80%) did not translate into improved OS or EFS in our study. These results may be owing to the low number of patients in the current study. As novel combination regimens 24 can potentially decrease the burden of disease, it is possible for increasing number of cardiac amyloidosis patients to undergo auto-SCT in future.
As cardiac biomarkers have an important role in prognostication as well as predicting the transplant outcomes, where AL patients with elevated cTnT or cTnI are reported to have a significantly higher risk of TRM, and recent studies indicate that patients with serum cTnT 40.06 ng/mL or an NT-proBNP 45000 pg/mL should not be considered as transplant candidates due to an unacceptable TRM, we systematically analyzed such cardiac biomarkers in our patient population and failed to demonstrate an impact of such biomarkers. We also utilized the Mayo staging system and did not show any significance. Other nonsignificant factors included achieving hematologic PR or VGPR before transplant, International Staging System at diagnosis, Hb o 10 g/dL, albumin o4 mg/dL, creatinine 41 mg/dL, beta-2 microglobulin 43.5 g/dL, LDH 4350 IU/L, cardiac event before transplant, ICU admission before transplant, mobilization complications, reducedintensity conditioning, NT-ProBNP 45000 ng/mL, BNP 4315 mg/ dL, cardiac stage ⩾ 3 and cardiac EF o60%. Such results may be owing to the retrospective nature of our study, the small number of patients, and the limited data available, especially in those who were previously treated outside institution before being referred to our center for transplant.
Not surprisingly, improved outcomes were seen more in younger patients than in those 460 years. This suggests that underlying organ dysfunction and comorbidity in older patients may result in excess toxicity and increased mortality after highdose chemotherapy. Also, younger patients should be considered earlier for transplant modality. Furthermore, lower disease burden as represented by low plasma cells in the BM also translated into improved outcomes. Our finding is similar to recent data reported by Kourelis et al., 25 where patients with AL with more than 10% plasma cells were shown to have a poor prognosis with 5-year OS of 19% as compared with 31% for AL only (P o0.001). We believe that due to small number of patients studied, incorporation of novel agents in induction therapy failed to show a significant trend toward improved OS. However, lack of correlation of survival outcomes with the degree of pre-transplant hematologic response suggests discordance between the BM disease and peripheral M-protein in cardiac AL patients, and this needs further investigation. As post-transplant hematologic relapse was a significant factor resulting in poor OS, early utilization of adjuvant therapy should be explored. 26, 27 In conclusion, from the encouraging hematologic and organ response rates accompanied by the high survival rate and low TRM, we conclude that it is feasible to perform HDT-ASCT in AL patients with cardiac involvement. In the era of novel therapeutic options, improved outcomes have been observed when careful patient selection is performed, especially at centers with extensive experience in treating patients with AL. 28 Larger studies with longer follow-up are needed to further explore these options. 
